{"nctId":"NCT00665366","briefTitle":"Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder","startDateStruct":{"date":"2008-06"},"conditions":["Bipolar Disorder Mania"],"count":493,"armGroups":[{"label":"Placebo + valproate or lithium","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Lithium","Drug: Valproate"]},{"label":"Aripiprazole + valproate or lithium","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Aripiprazole","Drug: Lithium","Drug: Valproate"]}],"interventions":[{"name":"Aripiprazole","otherNames":["Abilify","BMS-337039"]},{"name":"Placebo","otherNames":[]},{"name":"Lithium","otherNames":[]},{"name":"Valproate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key inclusion criteria:\n\n* Clinical diagnosis of bipolar I disorder mania, manic or mixed episode, with or without psychotic features\n* Current ongoing lithium or valproate treatment with the possibility of benefiting, based on the investigator's clinical judgment, from adjunctive treatment with aripiprazole\n* Therapeutic serum levels of lithium or valproate and a Young Mania Rating Total Score of 16 or higher at screening and baseline\n* Participants taking current lithium or valproate treatment combined with antipsychotic medication other than aripiprazole are acceptable, provided that the other antipsychotic medication is washed out at least 3 days prior to the blood draw for therapeutic plasma levels of lithium and valproate determination. Long-acting antipsychotics must be washed out prior to entering the double-blind treatment.\n\nKey exclusion criteria:\n\n* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the last dose of investigational product\n* A diagnosis of delirium, dementia, amnesia or other cognitive disorder, or a psychotic disorder\n* Current diagnosis of delirium, dementia, a cognitive disorder (ie, amnesia), or a psychotic disorder (ie, schizophrenia or schizoaffective disorder)\n* Current diagnosis of bipolar II disorder, bipolar disorder not otherwise specified, or any other primary psychiatric disorder other than bipolar I disorder mania\n* Thyroid pathology\n* Demonstrated cocaine abuse or dependence within the past 3 months prior to screening.\n* History of neuroleptic malignant syndrome from antipsychotic agents\n* Manic symptoms that investigator considers refractory to treatment\n* Previous nonresponsive (by investigator judgment) to aripiprazole for manic symptoms\n* Significant risk of suicide based on history, mental status exam, or investigator judgment.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)","description":"The YMRS is a clinician-administered scale, consisting of 11 multiple choice items, and used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-though disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.54","spread":"0.78"},{"groupId":"OG001","value":"-13.57","spread":"0.78"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)","description":"Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"0.08"},{"groupId":"OG001","value":"-0.93","spread":"0.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"0.09"},{"groupId":"OG001","value":"-1.46","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":"0.10"},{"groupId":"OG001","value":"-1.83","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.78","spread":"0.11"},{"groupId":"OG001","value":"-2.07","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Depression) Scale (LOCF Data Set)","description":"Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.01","spread":"0.05"},{"groupId":"OG001","value":"-0.09","spread":"0.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.06"},{"groupId":"OG001","value":"-0.01","spread":"0.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.04","spread":"0.07"},{"groupId":"OG001","value":"0.11","spread":"0.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.03","spread":"0.08"},{"groupId":"OG001","value":"0.14","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)","description":"Adjusted mean change. The CGI-BP is scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.51","spread":"0.11"},{"groupId":"OG001","value":"-1.59","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total and Subscale Scores on the Functional Assessment Short Test (FAST)(LOCF Data Set)","description":"The FAST is an interview-administered instrument used to assess the main functioning problems that patients with bipolar disorder experience. Participants are rated at Baseline, Week 3, Week 6, Week 9, and Week 12/End of Study Visit. The FAST consists of 24 items that assess impairment or disability in 6 specific areas of functioning, categorized as the subscales: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal (IP) relationships, and leisure time. All items are rated using a 4-point scale, 0=no difficulty, 1=mild difficulty, 2=moderate difficulty, and 3=severe difficulty. The global score is the sum of the scores of all items and ranges from 0 (0\\*24)to 96 (4\\*24). The higher the global score, the higher the level of impairment. function=functioning. LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.68","spread":"0.86"},{"groupId":"OG001","value":"-5.00","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.59","spread":"0.98"},{"groupId":"OG001","value":"-6.93","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.18","spread":"1.06"},{"groupId":"OG001","value":"-7.71","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.39","spread":"1.09"},{"groupId":"OG001","value":"-8.51","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"0.18"},{"groupId":"OG001","value":"-0.93","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.44","spread":"0.19"},{"groupId":"OG001","value":"-1.11","spread":"0.19"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.56","spread":"0.21"},{"groupId":"OG001","value":"-1.20","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.84","spread":"0.21"},{"groupId":"OG001","value":"-1.45","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.65","spread":"0.25"},{"groupId":"OG001","value":"-1.00","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.29"},{"groupId":"OG001","value":"-1.40","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.20","spread":"0.30"},{"groupId":"OG001","value":"-1.22","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"0.30"},{"groupId":"OG001","value":"-1.24","spread":"0.30"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.33","spread":"0.23"},{"groupId":"OG001","value":"-0.99","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.12","spread":"0.26"},{"groupId":"OG001","value":"-1.46","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"0.26"},{"groupId":"OG001","value":"-1.68","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.59","spread":"0.27"},{"groupId":"OG001","value":"-1.91","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.57","spread":"0.25"},{"groupId":"OG001","value":"-1.33","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.20","spread":"0.28"},{"groupId":"OG001","value":"-1.91","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.41","spread":"0.31"},{"groupId":"OG001","value":"-2.14","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.57","spread":"0.31"},{"groupId":"OG001","value":"-2.31","spread":"0.31"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.50","spread":"0.11"},{"groupId":"OG001","value":"-0.28","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.53","spread":"0.13"},{"groupId":"OG001","value":"-0.34","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.13"},{"groupId":"OG001","value":"-0.52","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.68","spread":"0.13"},{"groupId":"OG001","value":"-0.59","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.78","spread":"0.12"},{"groupId":"OG001","value":"-0.48","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.16","spread":"0.12"},{"groupId":"OG001","value":"-0.76","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.25","spread":"0.13"},{"groupId":"OG001","value":"-0.99","spread":"0.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.30","spread":"0.12"},{"groupId":"OG001","value":"-1.07","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Showing A Response From Baseline on the Young Mania Rating Scale (YMRS)(OC Data Set)","description":"Response on the YMRS is defined as a 50% or greater improvement from baseline in YMRS total score. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. OC=observed cases.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null},{"groupId":"OG001","value":"29.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null},{"groupId":"OG001","value":"49.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"64.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null},{"groupId":"OG001","value":"68.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Showing Remission in the Young Mania Rating Scale (YMRS) Score From Baseline (LOCF Data Set)","description":"Remission is defined as a YMRS total score of 12 or less. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.6","spread":null},{"groupId":"OG001","value":"31.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"51.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.0","spread":null},{"groupId":"OG001","value":"65.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"69.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)","description":"Adjusted mean change. The LIFE-RIFT total score ranges from 4 to 20 and is the sum of scores of 4 items: work, interpersonal relations, satisfaction, and recreation. A negative change score signifies improvement. OC=observed cases; LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.13","spread":"0.22"},{"groupId":"OG001","value":"-1.45","spread":"0.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.20","spread":"0.28"},{"groupId":"OG001","value":"-2.37","spread":"0.28"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.30","spread":"0.27"},{"groupId":"OG001","value":"-1.69","spread":"0.28"}]}]}]},{"type":"SECONDARY","title":"Participant Scores on Patient Global Impression Improvement (PGI-I) Scale (OC Data Set)","description":"Adjusted Mean Scores. The PGI-I is a self-administered 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. OC=observed cases.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.94","spread":"0.10"},{"groupId":"OG001","value":"2.99","spread":"0.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.39","spread":"0.11"},{"groupId":"OG001","value":"2.64","spread":"0.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"0.12"},{"groupId":"OG001","value":"2.24","spread":"0.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.60","spread":"0.13"},{"groupId":"OG001","value":"2.88","spread":"0.13"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participant Weight (OC Data Set and Week 12 LOCF Data Set)","description":"Adjusted mean change.OC=observed cases; LOCF=last observation carried forward.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.06","spread":"0.16"},{"groupId":"OG001","value":"0.14","spread":"0.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.02","spread":"0.20"},{"groupId":"OG001","value":"0.29","spread":"0.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":"0.26"},{"groupId":"OG001","value":"-0.01","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.29"},{"groupId":"OG001","value":"0.02","spread":"0.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.24"},{"groupId":"OG001","value":"0.11","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Relevant Weight Gain or Weight Loss From Baseline at Week 12 (LOCF Data Set)","description":"Relevant weight gain=7% or greater increase in weight; relevant weight loss=7% or greater decrease in weight. LOCF=last observation carried forward.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)","description":"BMI=Weight in kilograms /(Height in meters\\^2). LOCF=last observation carried forward.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":180},"commonTop":["Akathisia","Insomnia","Depression","Nausea","Headache"]}}}